Trial Profile
A Phase II Study of Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary) ; Tocilizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Jan 2023 Planned End Date changed from 31 Oct 2023 to 30 Jun 2027.
- 13 Jan 2023 Planned primary completion date changed from 31 Oct 2023 to 30 Jun 2027.
- 01 Feb 2022 Planned End Date changed from 30 Nov 2025 to 31 Oct 2023.